Trillium Therapeutics Inc.
Trillium Therapeutics Inc. (NASDAQ:TRIL, TSX:TR) is an immuno-oncology company developing innovative therapies for the treatment of cancer. Our lead program SIRPαFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system.